αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression

Currently ~50% of patients with a diagnosis of high-risk neuroblastoma will not survive due to relapsing or refractory disease. Recent innovations in immunotherapy for solid tumors are highly promising, but the low MHC-I expression of neuroblastoma represents a major challenge for T cell-mediated im...

Descripción completa

Detalles Bibliográficos
Autores principales: Strijker, Josephine G. M., Pscheid, Ronja, Drent, Esther, van der Hoek, Jessica J. F., Koopmans, Bianca, Ober, Kimberley, van Hooff, Sander R., Kholosy, Waleed M., Cornel, Annelisa M., Coomans, Chris, Bisso, Andrea, van Loenen, Marleen M., Molenaar, Jan J., Wienke, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471928/
https://www.ncbi.nlm.nih.gov/pubmed/34575700
http://dx.doi.org/10.3390/jpm11090923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471928/
https://www.ncbi.nlm.nih.gov/pubmed/34575700
http://dx.doi.org/10.3390/jpm11090923

Ejemplares similares